LENZ THERAPEUTICS INC
LENZNASDAQTrading Snapshot
- Day Range
- $5.17 – $5.31
- 52-Week Range
- $4.68 – $50.40
- Volume
- $2.95B
- Avg Volume
- $3.35B
- Shares Outstanding
- 31.4M
- Next Earnings
- Oct 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $5M
- P/E Ratio
- —
- P/S Ratio
- 8.0x
- EPS (TTM)
- $-3.59
- Dividend Yield
- —
Why Investors Own LENZ
- ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About LENZ THERAPEUTICS INC
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsDaniel Chevallard - Chief Financial OfficerEvert...
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. T
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.